Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT327 in Combination With Chemotherapy for Untreated ES-SCLC and Previously Treated SCLC
NCT06449209Phase 2Active, not recruiting
- Sponsor
- BioNTech SE
- Start
- Aug 2024
- Primary completion
- Jun 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of pumitamig in small cell lung cancer (SCLC), sponsored by BioNTech SE. Started Aug 2024; status: active, not recruiting.
02
Drugs
pumitamig
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06449209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06449209.